Longevity clinics are selling certainty the data cannot support

A typical longevity clinic visit produces an impressive volume of data: full-body imaging, an extensive blood panel, continuous glucose monitoring, and a composite score presenting the client's biological age as a single number. The presentation is confident. The science underneath it is considerably less so.

Researchers who study aging draw a hard line between two things the marketing tends to merge. Biomarkers are measurable and often genuinely informative about current physiology. Outcomes — whether an intervention extends healthy lifespan — require decades of follow-up that, for nearly every protocol these clinics sell, does not yet exist.

"We can measure a great deal," one researcher said. "What we cannot yet do is tell you that moving a particular number moves your life expectancy. Those are different claims, and only one of them is being sold."

The composite "biological age" score illustrates the gap. Several distinct methods for producing such a score exist, they disagree with one another when run on the same person, and none has been validated as a target that responds usefully to intervention. A number that moves is not the same as a number that matters.

Some of what these clinics do is uncontroversial and probably beneficial. Comprehensive screening catches conditions that routine care misses, and structured coaching on sleep, resistance training, and diet reflects the best-supported interventions available. Clinicians critical of the industry are generally not criticizing that part.

The concern concentrates on the tier above it: infusions, peptide protocols, hormone regimens, and supplement stacks priced in the thousands per month, most supported by small studies, animal models, or mechanistic reasoning rather than clinical endpoints. Several carry known risks that the sales conversation tends to compress into a footnote.

Whole-body imaging draws separate criticism. Scanning an asymptomatic person reliably finds incidental abnormalities, most of which are harmless, and each one generates follow-up testing carrying its own risk and cost. The clinical literature on population-level screening of this kind has been consistently unenthusiastic.

Regulators have been slow to define what these services may claim, in part because most operate in a gap between medical practice and wellness marketing. In the absence of clear rules, the working advice from researchers is unglamorous: pay for the screening and the coaching if you value them, treat the composite score as entertainment, and ask what clinical endpoint any recommended intervention has actually been shown to change.